Abstract

Efficacy of Dendritic Cell-Based Cancer Immunotherapy

Shigetaka Shimodaira, Yumiko Higuchi, Ryu Yanagisawa, Masato Okamoto and Shigeo Koido

Dendritic cells (DCs) have antigen-specific bioactivity against tumor-associated antigens. The acquisition of tumor immunity with DC vaccination could be determined using both tetramer analysis and interferon γ-producing clones in enzyme-linked immunosorbent spot assays. A combination of DC vaccination with low-dose metronomic therapy and chemoradiotherapy would contribute to an enhanced acquired immunity for cancer therapy. The efficacy of DC vaccination may provide a survival benefit in some patients with cancer by achieving a prolonged quality-adjusted life year.